💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Macitentan

CHEMBL2103873 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
588.3 g/mol
LogP
3.7
Phase
4

An endothelin receptor antagonist used to treat pulmonary arterial hypertension (PAH) by blocking the action of endothelin, a substance that causes blood vessels in the lungs to narrow. It helps improve exercise capacity and slow disease progression.

आणविक भार

588.3000 g/mol

LogP

3.70

TPSA

137.00 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

अल्ज़ाइमर रोग इंफ्लेमेटरी बाउल डिज़ीज़ उच्च रक्तचाप क्रॉनिक ऑब्सट्रक्टिव पल्मोनरी डिज़ीज़ (COPD) क्रॉनिक किडनी डिज़ीज़ गैस्ट्रोइसोफेजियल रिफ्लक्स रोग डीप वेन थ्रोम्बोसिस / पल्मोनरी एम्बोलिज़्म नॉन-अल्कोहलिक फैटी लिवर डिज़ीज़ पार्किंसन रोग श्वसन रोग संक्रामक रोग हृदय विफलता हृदय-संवहनी रोग

क्रिया का तंत्र

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCNS(=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1-c1ccc(Br)cc1

                

                

                
                

                    
InChI

                    
InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)

                

                

                

                    
                    

                        
Molecular Formula

                        
C19H20Br2N6O4S

                    

                    
                    

                        
HBD / HBA

                        
2 / 10

                    

                    
                    

                        
घूर्णनीय बंधन

                        
11

                    

                    
                    
                    

                        
भारी परमाणु

                        
32

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
An endothelin receptor antagonist used to treat pulmonary arterial hypertension (PAH) by blocking the action of endothelin, a substance that causes blood vessels in the lungs to narrow. It helps improve exercise capacity and slow disease progression.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Macitentan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2103873.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 16004692.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.